Conducting Clinical Trials During COVID-19: Lessons for the Next Pandemic

The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola, and other diseases called for the world to adjust and collaborate global research efforts. With COVID-19, the rapid spread and impact on global healthcare systems forced us to change our trial management and accelerate our processes like never before. The global research community have already discovered and developed several tests and vaccines in record time through collaboration. Yet we are still working on predictive biomarker testing to identify people who are at the most risk of developing severe symptoms, epidemiological, vaccine, and genetic studies.

To facilitate testing, research, and innovation and to ensure trials continued, Cerba Research and Cerba Healthcare adapted our capabilities and facilities to push research continuity.

Register for this webinar to learn the answers to these questions:

  • Did we succeed, how fast did we adapt, and are we ready to face a new pandemic crisis in the future?
  • How did we maintain the high security and confidence of testing, and what did our reactivity and proactivity mean in the context of a health crisis?

Webinar: Leveraging Medical Laboratory Data for Patient Recruitment

Connecting real-world laboratory data from clinical sites and digitalizing patient data – the power of Decentralized Clinical Trials (DCT) to change the trials of tomorrow

Digitalization continues to provide an impetus to move away from centralized, high-cost and difficult-to-access settings to more virtual, patient-centric and decentralized clinical trial (DCT) models. Our methods need to be more patient-centric, and we need to collaborate to find remote solutions.

Thanks to digitization, we can now decentralize clinical trials and put patient data in front of research success. In partnership with Biokortex, Cerba Research will show participants of this webinar a picture of the future: how clinical trials will look tomorrow. New technologies allow us to imagine a whole new process for drug development and assays. This new way of thinking reduces costs and enhance access to data.  The world is evolving fast, and we need to develop accordingly. Agility, adaptability and digitization need to be the new keywords for a more manageable and secure development.

Watch the recording of our webinar held in April 2021 to learn more!

Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development

“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”

– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research

Presence and Capabilities – Running Clinical Trials in Australia Infographic

Lab Support for the Largest Global Phase III NASH Study to Date

10-Day Study Start & Custom Test Kit Build at the Height of a Pandemic

Cerba Research initiated custom kit building & distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Phase 3 Clinical Trial on the Efficacy and Safety of a New Therapy For Post-Exposure Prophylaxis Of COVID-19 And Other Viral Respiratory Illnesses

Phase 3 Clinical Trial on the Safety and Efficacy Of Combination Therapies in Patients with Either Extensively Drug-Resistant Tuberculosis (XDR-TB), Pre-XDR-TB Or Treatment Intolerant Or Non- Responsive Multi-Drug Resistant Tuberculosis (MDR-TB)

Phase 3 Clinical Trial on the Efficacy and Safety of a New Therapy in the Treatment of Uncomplicated Influenza

Multiple Myeloma – Efficacy and Safety of 2 Different Combination Therapies